BTK Inhibitors in CLL: New Clinical Evidence Reshapes First-Line Treatment

BTK Inhibitors in CLL: New Clinical Evidence Reshapes First-Line Treatment   Check back later for a possible video summary. Videos are created for most articles.     Introduction The treatment landscape for chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries, has undergone a major shift with the advent of Bruton’s tyrosine kinase (BTK) inhibitors. These

Eosinophilic Dermatosis In Hematological Malignancy (EDHM): Case Study Reports

Eosinophilic Dermatosis In Malignancy (EDHM): Case Study Reports Overview Patients with hematological malignancies may develop various skin eruptions, and one such condition is eosinophilic dermatosis of hematological malignancy (EDHM), also known as an 'insect bite-like' reaction. While cutaneous reactions are not uncommon in hematological malignancies, EDHM is a relatively rare condition that

Acute Myeloid Leukemia And Diverse Patient Survival Outcomes

Acute Myeloid Leukemia And Diverse Patient Survival Outcomes Background Cancer remains a prominent global health concern, accounting for a significant number of cases and fatalities worldwide in 2020, with projections indicating further increases in both incidence and mortality rates, particularly in the United States. Hematologic malignancies (HMs) constitute a substantial subset of

BTK Inhibitors in CLL: New Clinical Evidence Reshapes First-Line Treatment